This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Thursday, August 22, 2013
Mental, physical health, fatigue worsened by antiviral therapy, anemia in HCV
Mental, physical health, fatigue worsened by antiviral therapy, anemia in HCV
August 21, 2013
Patients with chronic hepatitis C, particularly those with anemia, experienced significantly impaired mental and physical health and worsened fatigue symptoms while on antiviral therapy, with improvement coming at treatment completion in a recent study.
Researchers evaluated health-related quality of life (HRQL) and fatigue symptoms in 59 patients with HCV/HIV coinfection before, during and after therapy with pegylated interferon and ribavirin. Physical and mental health was measured via the Short Form (36) Health Survey; fatigue was assessed by the Fatigue Severity Scale.
Full Story »
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment